Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2017 May 1.

Published in final edited form as: Biol Psychiatry. 2015 Jun 5;79(9):746–754. doi: 10.1016/j.biopsych.2015.05.018

Table 2.

Sensitivity of NMDAR-mediated synaptic currents to GluN2B antagonist ifenprodil over early postnatal development.

		P15			P30			P45
		N/A Ratio	n	P	N/A Ratio	n	P	N/A Ratio	n	P
Pyramidal Neurons
Mecp2 WT	Control	1.18±0.08	15	^**	0.96±0.09	9	n.s.	0.92±0.05	13	n.s.
Mecp2 WT	Ifenprodil	0.83±0.09	12	^**	0.81±0.08	13	n.s.	0.82±0.05	14	n.s.
Mecp2 KO	Control	1.02±0.05	15	^**	0.96±0.07	11	^**	0.91±0.04	18	^*
Mecp2 KO	Ifenprodil	0.78±0.06	10	^**	0.64±0.08	9	^**	0.78±0.05	10	^*
Parvalbumin Interneurons
Mecp2 WT	Control	1.24±0.09	12	^**	0.75±0.06	11	^**	0.63±0.08	11	n.s.
Mecp2 WT	Ifenprodil	0.56±0.09	12	^**	0.47±0.06	11	^**	0.46±0.09	10	n.s.
Mecp2 KO	Control	1.06±0.08	13	^**	0.60±0.05	10	n.s.	0.66±0.07	12	n.s.
Mecp2 KO	Ifenprodil	0.66±0.09	10	^**	0.48±0.05	11	n.s.	0.55±0.07	13	n.s.

N/A Ratio = Ratio of NMDAR-/AMPAR-mediated synaptic currents; n=number of cells;

^**

P <0.01,

^*

P <0.02,

ANOVA with Bonferroni correction for multiple comparisons